# Harold Werner

> Harold Werner is a Series B investor at HealthCare Ventures backing Biotechnology and Medical. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [HealthCare Ventures](https://shizune.co/investors/profile/healthcare-ventures)
- Location: New York, United States
- Total investments: 5
- Last investment: Jun 2011
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/harold-werner-aa42217

Harold Werner is a Series B investor at HealthCare Ventures in New York focused on Biotechnology and Medical. Hal Werner is a Managing Director and Co-founder of HealthCare Ventures. Prior to the formation of HealthCare Ventures, Harold served as director of new ventures for Johnson & Johnson Development Corporation. Harold also has served as senior vice president of Robert S. First, Inc., an international health care consulting firm.Harold received his M.B.A. degree from Harvard University

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 40% |
| Medical | 1 | 20% |
| Health Care | 1 | 20% |
| Search Engine | 1 | 20% |
| Pharmaceutical | 1 | 20% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 40% |
| Series A | 1 | 20% |
| Series C | 1 | 20% |
| Debt Financing | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Stemgent | Stemgent works alongside some of the world's leading stem cell scientists in developing innovative technology and application solutions that provide researchers the tools to investigate and understand cellular reprogramming. Our mission is to help simplify and support stem cell research by producing products and services being designed byleading stem cell researchers.SpecialtiesCellular Reprogramming, iPS Cells, Media, Human iPSC Training & Services, mRNA Reprogramming, Stem Cell Research, Custom iPS cell lines, Pluriton, WIT, StainAlive, NutriStem | $10.6M | Series B | Jun 10, 2011 |  |
| Stemgent | Stemgent works alongside some of the world's leading stem cell scientists in developing innovative technology and application solutions that provide researchers the tools to investigate and understand cellular reprogramming. Our mission is to help simplify and support stem cell research by producing products and services being designed byleading stem cell researchers.SpecialtiesCellular Reprogramming, iPS Cells, Media, Human iPSC Training & Services, mRNA Reprogramming, Stem Cell Research, Custom iPS cell lines, Pluriton, WIT, StainAlive, NutriStem | $2.7M | Debt Financing | Nov 25, 2009 |  |
| InfaCare Pharmaceutical | InfaCare Pharmaceutical, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceuticals for the neonatal and pediatric patient population. Its neonatal product, Stanate, is under development for the pharmacologic treatment of infantile jaundice or hyperbilirubinemia. The company was founded in 2005 and isbased in Trevose, Pennsylvania. | $28M | Series B | Oct 28, 2008 |  |
| Stemgent | Stemgent works alongside some of the world's leading stem cell scientists in developing innovative technology and application solutions that provide researchers the tools to investigate and understand cellular reprogramming. Our mission is to help simplify and support stem cell research by producing products and services being designed byleading stem cell researchers.SpecialtiesCellular Reprogramming, iPS Cells, Media, Human iPSC Training & Services, mRNA Reprogramming, Stem Cell Research, Custom iPS cell lines, Pluriton, WIT, StainAlive, NutriStem | $6.5M | Series A | Jul 18, 2008 |  |
| Avidia | Avidia, Inc., a biopharmaceutical company, engages in discovering and developing therapeutic proteins. The company offers Avimer therapeutic proteins, which are used to address various therapeutic areas, including autoimmunity, inflammation, oncology, and neurology. Avidia, Inc. was founded in 2003 and is headquartered in Mountain View, California. | $43.8M | Series C | May 09, 2006 |  |

5 of 5 investments shown.

## Co-investors
- [Morgenthaler Ventures](https://shizune.co/investors/profile/morgenthaler-ventures) — VC Fund, 3 deals together
- [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures) — VC Fund, 1 deal together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 1 deal together
- [HealthCare Ventures](https://shizune.co/investors/profile/healthcare-ventures) — VC Fund, 1 deal together
- [Pequot Capital](https://shizune.co/investors/profile/pequot-capital) — VC Fund, 1 deal together
- [Skyline Ventures](https://shizune.co/investors/profile/skyline-ventures) — VC Fund, 1 deal together

## About HealthCare Ventures

VC Fund · Cambridge, United States

HealthCare Ventures is a leading life science venture capital firm investing in pre-clinical or early clinical stage, focused companies with potential to transform patient care.

5 contacts available at HealthCare Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| John Littlechild | Managing Director & General Partner | https://shizune.co/investors/profile/john-w-littlechild |
| Christopher K. Mirabelli | Managing Director | https://shizune.co/investors/profile/christopher-k-mirabelli |
| Douglas E. Onsi | Managing Director | https://shizune.co/investors/profile/douglas-e-onsi |
| Harold Werner | Co-Founder & Managing Director | https://shizune.co/investors/profile/harold-r-werner |
| James H. Cavanaugh | Managing Director | https://shizune.co/investors/profile/james-h-cavanaugh |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Harold Werner invest in?

Harold Werner invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series A stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Harold Werner last invest?

The most recent investment recorded for Harold Werner closed in Jun 2011. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co